Docoh
Loading...

MNMD Mind Medicine

News

From Benzinga Pro
MindMed Successfully Completes Phase 1 Trial Of 18-MC
19 Jan 22
Cannabis, Penny Stocks, Small Cap, Markets
This article was originally published on Microdose and appears here with permission.
Psychedelic Stock Gainers And Losers From January 18, 2022
18 Jan 22
Cannabis, Markets, Movers
GAINERS: Cybin (AMEX:CYBN) shares closed up 1.90% at $1.07
MindMed Launches Study Using Monitoring System For Psychedelic Experiences
18 Jan 22
Cannabis, Penny Stocks, Small Cap, Markets
Psychedelics biotech company MindMed (NASDAQ: MNMD) has enrolled the first subjects into its Session Monitoring System study. The company’s Session Monitoring System is a technology platform that can collect sensory data during a therapy session with a psychedelic drug.
Stocks That Hit 52-Week Lows On Tuesday
18 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
Tuesday morning saw 454 companies set new 52-week lows.
Cannabis Movers & Shakers: MindMed, Halo Collective, Item 9, PSYC, Flora Growth
10 Jan 22
Cannabis, News, Penny Stocks, Entrepreneurship, Movers & Shakers, Small Cap, Markets, General
Stephen Hurst Steps Down From MindMed's Board Of Directors Psychedelic-focused biotech company Mind Medicine Inc (NASDAQ: MNMD) announced on Friday that Stephen Hurst has resigned from his role as director of the company's board.
Psyched: Canada's Access To Psychedelic Medicines, Psilocybin No Cognitive Side Effects, Psilocybin Bill Washington
10 Jan 22
Cannabis, Penny Stocks, Small Cap, Markets
Canada Opens New Legal Pathways For Access To Treatment With Psilocybin And MDMA
Stocks That Hit 52-Week Lows On Thursday
6 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Thursday, 615 stocks hit new 52-week lows.
MindMed Completes Phase 1 Clinical Trial Of Non-Hallucinogenic Proprietary Derivative Of Ibogaine
4 Jan 22
Cannabis, News, Penny Stocks, Small Cap, Markets
On Tuesday, Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) reported the completion of its Phase 1 clinical trial of 18-MC, the company’s non-hallucinogenic proprietary derivative of ibogaine, being developed for the treatment of indications linked to opioid use d
2021 Was The Year Psychedelics Conquered Capitalism...Or Is It The Other Way Around?
30 Dec 21
Cannabis, News, Topics, Markets, General
Witnessing an entirely new industry being created from scratch is a rare and historic event, one that brings with it tremendous opportunity for investors and entrepreneurs alike.
Cannabis Movers & Shakers: MindMed & Trulieve Management Shake-Ups, Credex Corp & CapStone Bolster Leadership Teams
29 Dec 21
Cannabis, News, Entrepreneurship, Movers & Shakers, Markets, General
MindMed Announces Management Shake-Ups Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a psychedelic-based biotech company, announced Wednesday that Bradford Cross, its chief technology officer, has transitioned from his role.
MindMed Shares Update On Phase 2b Trials of LSD For Treating Generalized Anxiety Disorder
22 Dec 21
News, Penny Stocks, Small Cap, FDA
MindMed (NASDAQ: MNMD) (NEO: MMED),
'Another Washington City Moves To Decriminalize Psychedelics, With Unanimous Council Vote' -Marijuana Moment Report
21 Dec 21
Cannabis, News, Politics, Legal, Markets, General
https://www.marijuanamoment.net/another-washington-city-moves-to-decriminalize-psychedelics-with-unanimous-council-vote/
'GOP Lawmakers File Bills To Streamline Research Into Marijuana, Psychedelics And Other Schedule I Drugs: "One of the things we've done in the past is we've put things on Schedule I and then we've not researched it."' -Marijuana Moment
21 Dec 21
Cannabis, News, Rumors, Politics, Markets, Media, General
https://www.marijuanamoment.net/gop-lawmakers-file-bills-to-streamline-research-into-marijuana-psychedelics-and-other-schedule-i-drugs/
MindMed Announces FDA Has Issued A Clinical Hold On Initial IND Submission For Phase 2b Trial Of LSD For Treatment of Generalized Anxiety Disorder
21 Dec 21
Biotech, News, FDA, General
- FDA has issued a clinical hold on initial IND submission required to initiate Phase 2b trial of LSD for the treatment of generalized anxiety disorder - NEW YORK, Dec. 21, 2021 /PRNewswire/
'Activists File Colorado Ballot Initiatives To Legalize Psychedelics And Establish 'Healing Center' Program' -Marijuana Moment Report
17 Dec 21
Cannabis, Politics, Markets, General
https://www.marijuanamoment.net/activists-file-colorado-ballot-initiatives-to-legalize-psychedelics-and-establish-healing-center-program/
MindMed Advances Phase 2a LSD Microdose Trial For Adult ADHD
17 Dec 21
Biotech, Cannabis, News, Penny Stocks, Small Cap, Markets, General
Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Friday the initiation of Phase 2a proof-of-concept trial of LSD (lysergic acid diethylamide) in adult patients with attention deficit hyperactivity disorder.
'Congressman Asks Colleagues To Demand DEA Allow Psilocybin Treatment For Terminal Patients' -Marijuana Moment Report
17 Dec 21
Cannabis, Politics, Markets, General
https://www.marijuanamoment.net/congressman-asks-colleagues-to-demand-dea-allow-psilocybin-treatment-for-terminal-patients/
MindMed Reports Initiation Of Phase 2a LSD Trial For Treatment Of Adult ADHD
17 Dec 21
Biotech, News, FDA, General
- Enrolling patients in proof-of-concept exploratory trial conducted in collaboration with the University Hospital Basel in Switzerland and Maastricht University in the Netherlands – -Trial led by Dr. Matthias
Cannabis Movers & Shakers: HEXO, Agrify, MindMed, KetamineOne
15 Dec 21
Cannabis, News, Penny Stocks, Entrepreneurship, Movers & Shakers, Small Cap, Markets, General
Agrify Taps Barry Turkanis To Its Board Of Directors Vertically integrated cannabis company Agrify Corporation (NASDAQ: AGFY) announced Tuesday that it has appointed Barry Turkanis to serve as an independent director on its board of directors.
Watching Psychedelics Therapy Stocks COMPASS Pathways And MindMed Following Marijuana Moment Report 'New York Lawmaker Files Bill To Legalize Medical Psilocybin Treatments, With Focus On First Responders And Veterans...'
14 Dec 21
Cannabis, News, Rumors, Markets, Media, Trading Ideas
https://www.marijuanamoment.net/new-york-lawmaker-files-bill-to-legalize-medical-psilocybin-treatments-with-focus-on-first-responders-and-veterans/

Press releases

From Benzinga Pro
Psilocybin and MDMA Get the Green Light for Medical Use in Canada
19 Jan 22
Small Cap, Opinion, Press Releases
NEW YORK, Jan. 19, 2022 /PRNewswire/ -- After facing legal scrutiny for decades, psychedelics including MDMA and psilocybin received a stamp of approval from Health Canada for medical purposes. Canada's legislation
MindMed Enrolls First Participant in a Study of its Session Monitoring System
18 Jan 22
Press Releases
NEW YORK, Jan. 18, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for
Stephen Hurst Resigns from MindMed Board of Directors
7 Jan 22
Press Releases
NEW YORK, Jan. 7, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-derived therapies, announces the
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC
4 Jan 22
Press Releases
- Last subject completed study in late 2021 with topline results expected in early 2022 - - Results to inform design of Phase 2a study in individuals undergoing supervised opioid withdrawal - NEW YORK, Jan. 4, 2022
MindMed to Participate at the LifeSci Partners 11th Annual Corporate Access Event
30 Dec 21
Press Releases
NEW YORK, Dec. 30, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced
MindMed Announces Transitions to Management Team
29 Dec 21
Press Releases
- Bradford Cross, Chief Technology Officer to transition; Don Gehlert, PhD, Chief Scientific Officer to transition to Senior Scientific Advisor - NEW YORK, Dec. 29, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc.
MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder
21 Dec 21
Press Releases
- FDA has issued a clinical hold on initial IND submission required to initiate Phase 2b trial of LSD for the treatment of generalized anxiety disorder - NEW YORK, Dec. 21, 2021 /PRNewswire/ -- Mind Medicine (MindMed)
MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD
17 Dec 21
Press Releases
- Enrolling patients in proof-of-concept exploratory trial conducted in collaboration with the University Hospital Basel in Switzerland and Maastricht University in the Netherlands – -Trial led by Dr. Matthias Liechti
North American Psychedelic Drugs Market Expected To Reach A Value Of $3.184 Billion In 2026
14 Dec 21
Opinion, Press Releases
PALM BEACH, Fla., Dec. 14, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept pace,
MindMed Appoints Robert Barrow as Chief Executive Officer and Director
14 Dec 21
Press Releases
-Mr. Barrow previously served as interim Chief Executive Officer and Chief Development Officer of MindMed -Carol Vallone appointed as Chair of the Board of Directors, Andreas Krebs appointed as Vice Chair and Perry
MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System
9 Dec 21
Press Releases
NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies recently met with the
MindMed to Participate at the Benzinga Global Small Cap Conference
2 Dec 21
Press Releases
NEW YORK, Dec. 2, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that
MindMed to Present at H.C. Wainwright 2nd Annual Psychedelics Conference
1 Dec 21
Press Releases
NEW YORK, Dec. 1, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that
MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin
30 Nov 21
Press Releases
NEW YORK, Nov. 30, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (DE: MMQ); (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to
Intranasal Ketamine Garnering A lot of Attention as an Effective Treatment For Depression
23 Nov 21
Small Cap, Opinion, Press Releases
PALM BEACH, Fla., Nov. 23, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The COVID-19 pandemic is expected to have a significant positive impact on the growth of the global antidepressant market. The
MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures
16 Nov 21
Press Releases
NEW YORK, Nov. 16, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD, NEO: MMED, DE: MMQ, the ", Company", )), a leading biotech company developing psychedelic-inspired therapies, is pleased to
MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline
15 Nov 21
Earnings, Press Releases
NEW YORK, Nov. 15, 2021 /PRNewswire/ -- MindMed (NASDAQ:MNMD, NEO: MMED, DE: MMQ)), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended
MindMed to Present at the Jefferies London Healthcare Conference
12 Nov 21
Press Releases
NEW YORK, Nov. 12, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to
This Could Be The Next Multi-Billion AI Breakthrough
5 Nov 21
Opinion, Press Releases
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary LONDON, Nov. 5, 2021 /PRNewswire/ -- There's a massive announcement set to take place later this year, and it could change the $12 trillion
MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board
5 Nov 21
Press Releases
NEW YORK, Nov. 5, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (NEO: MMED) (DE: MMQ) the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce